Project: A revolutionary HLA-open conformer specific antibody for chronic inflammatory rheumatic diseases
| Acronym | blOCk (Reference Number: 114979) |
| Duration | 01/05/2021 - 01/11/2023 |
| Project Topic | blOCk will deliver OCi, the revolutionary therapeutic antibody to treat immune-mediated inflammatory diseases starting with spondyloarthritis (SpA). For the first time, OCi will target HLA open conformers (HLA-OCs), a causative mechanism of inflammation. OCi works upstream of all current suboptimal therapies that only 30-50% of patients respond to. By the project end we will have an optimized and validated lead antibody, ready to enter IND/CTA-enabling preclinical testing. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 14 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Academic Medical Center | Partner | Netherlands |
| 2 | ImmunOs Therapeutics AG | Coordinator | Switzerland |
| 3 | ProteoGenix SAS | Partner | France |